Embecta (EMBC) Competitors $14.10 -0.31 (-2.15%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$15.21 +1.11 (+7.87%) As of 02/21/2025 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends EMBC vs. WRBY, LIVN, ENOV, NVCR, TMDX, LMAT, TNDM, SLNO, CNMD, and CDREShould you be buying Embecta stock or one of its competitors? The main competitors of Embecta include Warby Parker (WRBY), LivaNova (LIVN), Enovis (ENOV), NovoCure (NVCR), TransMedics Group (TMDX), LeMaitre Vascular (LMAT), Tandem Diabetes Care (TNDM), Soleno Therapeutics (SLNO), CONMED (CNMD), and Cadre (CDRE). These companies are all part of the "medical equipment" industry. Embecta vs. Warby Parker LivaNova Enovis NovoCure TransMedics Group LeMaitre Vascular Tandem Diabetes Care Soleno Therapeutics CONMED Cadre Warby Parker (NYSE:WRBY) and Embecta (NASDAQ:EMBC) are both consumer staples companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, community ranking, earnings, dividends, media sentiment, valuation, profitability and institutional ownership. Which has preferable valuation and earnings, WRBY or EMBC? Embecta has higher revenue and earnings than Warby Parker. Warby Parker is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioWarby Parker$742.53M3.29-$63.20M-$0.27-89.00Embecta$1.12B0.73$78.30M$1.0014.10 Which has more risk & volatility, WRBY or EMBC? Warby Parker has a beta of 1.9, meaning that its share price is 90% more volatile than the S&P 500. Comparatively, Embecta has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Does the media refer more to WRBY or EMBC? In the previous week, Warby Parker had 3 more articles in the media than Embecta. MarketBeat recorded 9 mentions for Warby Parker and 6 mentions for Embecta. Warby Parker's average media sentiment score of 0.54 beat Embecta's score of 0.34 indicating that Warby Parker is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Warby Parker 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Embecta 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts rate WRBY or EMBC? Warby Parker presently has a consensus target price of $21.92, indicating a potential downside of 8.76%. Embecta has a consensus target price of $23.00, indicating a potential upside of 63.12%. Given Embecta's higher probable upside, analysts plainly believe Embecta is more favorable than Warby Parker.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Warby Parker 1 Sell rating(s) 5 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.50Embecta 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is WRBY or EMBC more profitable? Embecta has a net margin of 5.25% compared to Warby Parker's net margin of -4.39%. Warby Parker's return on equity of -8.26% beat Embecta's return on equity.Company Net Margins Return on Equity Return on Assets Warby Parker-4.39% -8.26% -4.37% Embecta 5.25%-19.22%11.92% Does the MarketBeat Community prefer WRBY or EMBC? Warby Parker received 39 more outperform votes than Embecta when rated by MarketBeat users. Likewise, 42.11% of users gave Warby Parker an outperform vote while only 6.25% of users gave Embecta an outperform vote. CompanyUnderperformOutperformWarby ParkerOutperform Votes4042.11% Underperform Votes5557.89% EmbectaOutperform Votes16.25%Underperform Votes1593.75% Do insiders and institutionals have more ownership in WRBY or EMBC? 93.2% of Warby Parker shares are held by institutional investors. Comparatively, 93.8% of Embecta shares are held by institutional investors. 26.5% of Warby Parker shares are held by insiders. Comparatively, 0.4% of Embecta shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryWarby Parker beats Embecta on 9 of the 17 factors compared between the two stocks. Get Embecta News Delivered to You Automatically Sign up to receive the latest news and ratings for EMBC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EMBC vs. The Competition Export to ExcelMetricEmbectaSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$819.69M$4.71B$5.85B$9.15BDividend Yield3.88%39.90%4.76%3.85%P/E Ratio14.1014.9116.5114.19Price / Sales0.7452.72450.0276.60Price / Cash4.3251.1038.0134.95Price / Book-1.076.577.644.63Net Income$78.30M$90.13M$3.18B$245.69M7 Day Performance-5.05%-2.20%-1.95%-2.68%1 Month Performance-24.76%-2.17%-0.23%-2.16%1 Year Performance-4.41%15.26%16.69%12.90% Embecta Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EMBCEmbecta4.807 of 5 stars$14.10-2.2%$23.00+63.1%-5.7%$819.69M$1.11B14.102,100Short Interest ↓High Trading VolumeWRBYWarby Parker2.5521 of 5 stars$25.70-2.7%$21.77-15.3%+71.6%$2.61B$669.77M-95.193,491Upcoming EarningsAnalyst ForecastLIVNLivaNova3.5845 of 5 stars$47.68+0.1%$69.17+45.1%-16.5%$2.59B$1.15B113.522,900Upcoming EarningsENOVEnovis3.4615 of 5 stars$43.89+0.4%$64.83+47.7%-29.1%$2.50B$1.71B-20.046,550Short Interest ↓Positive NewsNVCRNovoCure3.4827 of 5 stars$22.48+3.5%$32.67+45.3%+41.4%$2.43B$509.34M-16.061,453Upcoming EarningsNews CoverageTMDXTransMedics Group3.6199 of 5 stars$72.18+1.3%$122.70+70.0%-17.3%$2.42B$241.62M76.79210News CoverageGap UpLMATLeMaitre Vascular2.0498 of 5 stars$98.65+1.7%$94.63-4.1%+59.9%$2.22B$193.48M53.91490Positive NewsTNDMTandem Diabetes Care4.0971 of 5 stars$33.47+2.6%$53.81+60.8%+37.5%$2.20B$747.72M-17.342,400Positive NewsSLNOSoleno Therapeutics4.5423 of 5 stars$49.17-4.2%$71.20+44.8%-5.1%$2.12BN/A-14.8130News CoveragePositive NewsCNMDCONMED4.7777 of 5 stars$63.05-2.1%$77.20+22.4%-25.1%$1.95B$1.31B14.874,000CDRECadre2.9308 of 5 stars$35.14-1.6%$39.67+12.9%-5.2%$1.43B$482.53M42.342,435 Related Companies and Tools Related Companies WRBY Alternatives LIVN Alternatives ENOV Alternatives NVCR Alternatives TMDX Alternatives LMAT Alternatives TNDM Alternatives SLNO Alternatives CNMD Alternatives CDRE Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EMBC) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Embecta Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Embecta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.